BioCardia Inc. (NASDAQ: BCDA)
$3.18
-0.3650 ( -10.30% ) 137.9K
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
Market Data
Open
$3.18
Previous close
$3.54
Volume
137.9K
Market cap
$5.84M
Day range
$2.88 - $3.44
52 week range
$2.62 - $38.10
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 14 | Sep 06, 2023 |
8-k | 8K-related | 14 | Sep 05, 2023 |
def | Proxies and info statements | 5 | Sep 01, 2023 |
8-k | 8K-related | 13 | Aug 21, 2023 |
4/a | Other | 1 | Aug 18, 2023 |
4/a | Other | 1 | Aug 18, 2023 |
4 | Insider transactions | 1 | Aug 17, 2023 |
4 | Insider transactions | 1 | Aug 14, 2023 |
8-k | 8K-related | 14 | Aug 09, 2023 |
10-q | Quarterly Reports | 61 | Aug 09, 2023 |